Phase II study of imatinib mesylate [imatinib; Gleevec) (NSC-716051) in combination with capecitabine (Xeloda) (NSC-712807) In Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2011
At a glance
- Drugs Capecitabine (Primary) ; Imatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2005 New trial record.